What is PT-141?
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin agonist. A licensed on-demand product exists for HSDD in some markets. Research vials are not that product. All catalog material is for laboratory research use only.
Browse / PT-141
PT-141
Bremelanotide · melanocortin agonist
Injectable
1.75mg, custom
custom
APPROVED INDICATION (DRUG)
Overview
Key Benefits
Melanocortin agonist, CNS sexual-function literature, Licensed drug exists separately
Mechanism of Action
Central MC3R/MC4R activation is the proposed pathway for sexual-function research, distinct from vascular PDE5 mechanisms.
Molecular Information
- Weight
- 1025.2 g/mol
- Length
- 8 amino acids
- Type
- Bremelanotide (Melanocortin Receptor Agonist)
- Formula
- C50H68N14O10
Amino Acid Sequence
Ac-Nle-Cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH
Research directions
Sexual function Approved indication (drug)
- HSDD trials of bremelanotide
Pharmacokinetics
Peak ~1 h (licensed SC product)
Half-life ~2.7 h
Cleared within a day
PK of the approved presentation.
Literature
- Bremelanotide HSDD — 2019 · Clinical. Approved melanocortin agonist trials.